← Browse by Condition
Medical Condition

prostatic neoplasms

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for prostatic neoplasms sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

  • Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
  • Phase 1–4 studies from early safety trials to post-marketing surveillance
  • NIH, pharmaceutical sponsor, and academic medical center studies worldwide
  • AI-powered plain-language summary available for every trial listing

Frequently Asked Questions — prostatic neoplasms Clinical Trials

How many clinical trials are currently recruiting for prostatic neoplasms?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for prostatic neoplasms, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for prostatic neoplasms?
prostatic neoplasms research spans Phase 1 (1 trial), Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a prostatic neoplasms clinical trial?
Eligibility criteria for prostatic neoplasms trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
1
Phase 3
1
Top Sponsors
Janssen Research & Development, LLC 1 trial
Dana-Farber Cancer Institute 1 trial
Royal North Shore Hospital 1 trial
Merck Sharp & Dohme LLC 1 trial

Recruiting Clinical Trials

NCT07082920 Phase 1
Recruiting

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

Enrollment
140 pts
Location
United States, Unite...
Sponsor
Janssen Research & Development...
View Trial →
NCT05765500 Phase 2
Recruiting

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

Enrollment
110 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
View Trial →
NCT06547398
Recruiting

Prostate Adaptive Radiation Therapy

Enrollment
130 pts
Location
Australia
Sponsor
Royal North Shore Hospital
View Trial →
NCT06925737 Phase 3
Recruiting

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Enrollment
1,440 pts
Location
United States, Argen...
Sponsor
Merck Sharp & Dohme LLC
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology